STOCK TITAN

Humanigen, Inc. - HGEN STOCK NEWS

Welcome to our dedicated page for Humanigen news (Ticker: HGEN), a resource for investors and traders seeking the latest updates and insights on Humanigen stock.

Humanigen, Inc. (OTC Pink: HGEN) is a clinical-stage biopharmaceutical company advancing novel therapies for critical medical conditions. This page serves as the definitive source for verified news and press releases related to the company’s development of lenzilumab and other pipeline candidates.

Access timely updates on clinical trial progress, including the Phase 2/3 RATinG study for acute Graft versus Host Disease (aGvHD) and developments in CAR-T therapy toxicity mitigation. Stay informed about strategic partnerships with leading research institutions and regulatory milestones.

Key content areas include trial result announcements, financial updates, collaborative research initiatives, and therapeutic mechanism insights. All information is sourced directly from company filings and verified channels to ensure accuracy.

Bookmark this page for streamlined access to essential updates about Humanigen’s innovative antibody therapies. For comprehensive details, visit the company’s official website and follow their corporate communications channels.

Rhea-AI Summary

Humanigen, Inc. (Nasdaq: HGEN) has appointed Ken Trbovich as the SVP of Investor Relations, effective immediately. Trbovich brings over 20 years of Wall Street experience as a Managing Director and Senior Analyst from notable investment banks. He will play a key role in engaging with investors while Humanigen prepares for potential Emergency Use Authorization for its drug lenzilumab, aimed at treating cytokine storms in COVID-19 patients. Humanigen's focus also includes exploring lenzilumab's efficacy in various inflammatory conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.3%
Tags
none
-
Rhea-AI Summary

Humanigen, Inc. (Nasdaq: HGEN) announced its participation at the 2021 LD Micro Invitational XI from June 8-10, 2021. The company will present on June 8 during the 'Hall of Fame' session, discussing its lead drug candidate, lenzilumab, which aims to treat cytokine storms in COVID-19 patients. Lenzilumab has been submitted for Emergency Use Authorization by the FDA. The presentation will also cover launch preparations and updates on other development programs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.79%
Tags
conferences
-
Rhea-AI Summary

Humanigen, Inc. (Nasdaq:HGEN) announced the submission of an Emergency Use Authorization (EUA) application to the FDA for its lead drug candidate, lenzilumab, aimed at treating hospitalized COVID-19 patients. This follows encouraging results from the LIVE-AIR Phase 3 trial, where lenzilumab showed a 54% improvement in the likelihood of survival without ventilation. The drug's safety profile was comparable to placebo, and it is positioned to address a critical need for effective COVID-19 treatments. Humanigen is also pursuing further clinical studies for its therapies targeting cancers and other diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.04%
Tags
covid-19
Rhea-AI Summary

Humanigen, Inc. (Nasdaq: HGEN) announced that data on GM-CSF gene-edited CAR-T cells will be presented at the ISCT 2021 Annual Meeting in New Orleans from May 26-28, 2021. Researchers from the Mayo Clinic highlighted that GM-CSF knock-out in CAR-T cells reduces activation-induced cell death and enhances T-cell expansion in vivo, promising improved anti-tumor activity. CEO Cameron Durrant emphasized the potential of GM-CSFKO CAR-T as a less toxic alternative to current therapies. The Mayo Clinic's presentation is scheduled for May 28, 2021, from 11:30 AM to 1:00 PM ET.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.35%
Tags
none
-
Rhea-AI Summary

Humanigen, Inc. (Nasdaq: HGEN) announced its management team will participate in a fireside chat at the Jefferies Healthcare Conference from June 1-4, 2021. They will discuss the lead product, lenzilumab, which has completed a Phase 3 trial for COVID-19 patients. The chat will cover the submission for Emergency Use Authorization to the FDA and updates on commercial preparations. The live session is scheduled for June 2, 2021, at 4:00 PM ET. Additionally, the company plans to launch a Phase 2 study on lenzilumab combined with CD19 CAR-T therapies for lymphoma.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.73%
Tags
conferences
-
Rhea-AI Summary

Humanigen (Nasdaq:HGEN) has partnered with Chime Biologics to produce its lead drug candidate, lenzilumab, for commercial sale outside the U.S. The agreement follows the positive results from the LIVE-AIR Phase 3 clinical trial. Chime will utilize its advanced KuBio facility in China, with an initial capacity of 56,000L for annual production. The planned commercial product availability is set for 2022, pending necessary regulatory approvals in regions like Europe, India, and Brazil. This collaboration aims to fulfill the anticipated demand for lenzilumab.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.03%
Tags
covid-19
Rhea-AI Summary

Humanigen announced its Q1 2021 financial results, reporting a net loss of $65.6 million or $1.25 per share, up from $2.5 million or $0.11 per share in Q1 2020. The loss was primarily due to increased R&D expenses of $59.9 million, mainly for lenzilumab manufacturing and clinical trials. The company successfully completed its Phase 3 LIVE-AIR study for lenzilumab, showing a 54% greater likelihood of survival for treated COVID-19 patients. Humanigen plans to submit for emergency use authorization (EUA) for lenzilumab by May 2021 and has raised $94.1 million from a recent public offering.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.04%
Tags
-
Rhea-AI Summary

Humanigen, Inc. (Nasdaq: HGEN) announced the online publication of results from its Phase 3 study, LIVE-AIR, evaluating lenzilumab in hospitalized COVID-19 patients. This study supports lenzilumab's potential to treat cytokine storm, a severe immune response. Humanigen plans to initiate a Phase 2 study assessing lenzilumab's efficacy alongside CD19 CAR-T therapies for diffuse large B-cell lymphoma. The company is also advancing gene-edited CAR-T therapies and examining GM-CSF neutralization technologies to enhance treatment efficacy while controlling toxicity.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.43%
Tags
clinical trial covid-19
-
Rhea-AI Summary

Humanigen, Inc. (Nasdaq: HGEN) has appointed Adrian Kilcoyne, MD, MBA, MPH, as its Chief Medical Officer, effective immediately. Dr. Kilcoyne previously held significant roles at AstraZeneca, overseeing multiple oncology launches, and brings expertise in clinical development across various therapeutic areas. His role will involve leading clinical and regulatory strategies for Humanigen's lead drug candidate, lenzilumab, aimed at treating conditions like acute GvHD and COVID-19. This strategic appointment is seen as a move to strengthen Humanigen's leadership in developing innovative therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.71%
Tags
management
Rhea-AI Summary

Humanigen, Inc. (Nasdaq: HGEN) reported promising data from the Phase 1b ZUMA-19 study, evaluating its drug, lenzilumab, in patients with diffuse large B-cell lymphoma (DLBCL) undergoing CAR-T therapy. At the recommended Phase 2 dose of 1,800 mg, the objective response rate (ORR) reached 100% with no severe cytokine release syndrome (CRS) or neurological toxicity. The company plans a larger, potentially registrational Phase 2 trial to assess lenzilumab with various CD19 CAR-T therapies, enrolling approximately 150 patients. The collaboration with Kite on ZUMA-19 has been terminated.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.7%
Tags

FAQ

What is the market cap of Humanigen (HGEN)?

The market cap of Humanigen (HGEN) is approximately 23.8K.
Humanigen, Inc.

Nasdaq:HGEN

HGEN Rankings

HGEN Stock Data

23.82k
110.48M
10.35%
0.49%
3.48%
Biotechnology
Healthcare
Link
United States
Short Hills